Supplementary Table S1. Differences between patients on TNFα inhibitors and those on other therapies

Variable	TNFα inhibitors n= 26	Other therapies n=120	*p-value*
Baseline demographic and epidemiological characteristics			
Age in years, mean (SD)	54.9 (9.4)	55.9 (12.05)	0.647
Sex (women), n (%)	19 (73.1)	93 (77.5)	0.628
Smoking status			0.488
Never smoker, n (%)	17 (65.4)	69 (57.5)	-
Ex-smoker, n (%)	2 (7.7)	20 (16.6)	-
Active smoker n (%)	5 (19.2)	26 (21.6)	-
Body mass index (Kg/m^2), mean (SD)	30.3 (7.9)	26.6 (4.7)	**0.040**
Comorbidities			
Hypertension, n (%)	3 (11.5)	40 (33.3)	**0.027**
Diabetes mellitus, n (%)	1 (3.8)	3 (2.5)	0.703
Heart disease, n (%)	0	2 (1.7)	0.498
Dyslipidaemia, n (%)	5 (19.2)	41 (34.1)	0.137
Lab results			
Uric acid (mg/dl), mean (SD)	4.9 (1.4)	4.4 (1.3)	0.226
Total cholesterol (mg/dl), mean (SD)	208.5 (36.7)	195.7 (37.4)	0.119
LDL cholesterol (mg/dl), mean (SD)	126.8 (32.9)	117.1 (29.5)	0.176
HDL cholesterol (mg/dl), mean (SD)	59.8 (13)	59.4 (18.8)	0.891
Triglycerides (mg/dl), mean (SD)	105 (46.2)	102.1 (47.7)	0.733
Apolipoprotein A1 (mg/dl), mean (SD)	151 (29.8)	150.2 (33.1)	0.906
Apolipoprotein B (mg/dl), mean (SD)	98.5 (26.5)	83.7 (20.03)	**0.016**
ApoB/ApoA1, mean (SD)	0.7 (0.36)	0.57 (0.2)	0.105
Homocysteine (mg/L), mean (SD)	1.9 (0.55)	3.3 (4.1)	**0.018**
ESR (mm/h) at visit, mean (SD)	16.8 (12.7)	16.8 (14.8)	0.992
2-year mean ESR, mean (SD)	18.02 (10.8)	17.4 (12.4)	0.824
CRP (mg/dl) at visit, mean (SD)	8.41 (7.6)	8.9 (14.5)	0.781
2-year mean CRP, mean (SD)	9.2 (8.9)	9.8 (12)	0.782
Characteristics of the disease			
Disease duration of RA (years), mean (SD)	9.9 (7.2)	8.6 (8.3)	0.419
Rheumatoid factor positive, n (%)	19 (73.1)	105 (87.5)	**0.035**
Anti-CCP positive, n (%)	21 (80.7)	103 (85.8)	0.512
Anti-CCP level, mean (SD)	310.1 (807)	317 (439)	0.966
RF level, mean (SD)	102.8 (105)	116.4 (193.2)	0.627
Cumulative DAS28, mean (SD)	3.21 (1.3)	2.9 (1.2)	0.333
Remission-low activity, n (%)	13 (50)	62 (51.6)	0.346
Cumulative CDAI, mean (SD)	13.3 (8.8)	10.3 (6.8)	0.119
Cumulative SDAI, mean (SD)	13.9 (8.8)	11.2 (7.3)	0.151
HAQ at visit, mean (SD)	1.05 (0.29)	0.73 (0.7)	0.059
Carotid ultrasound			
CIMT, mean (SD)	0.58 (0.1)	0.65 (0.2)	**0.013**
Atheromatous plaque, n (%)	6 (23.1)	42 (35.8)	0.202
Bilateral distribution of plaque, n (%)	1 (3.8)	15 (12.5)	0.185

Abbreviations: LDL: low-density lipoprotein; HDL: high-density lipoprotein; ApoB: apolipoprotein B; ApA1: apolipoprotein A1; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; anti-CCP: anti-cyclic citrullinated peptide, DAS28: 28-joint Disease Activity Score; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; HAQ Health Assessment Questionnaire; bDMARD: biological disease-modifying antirheumatic drug; tsDMARD: targeted synthetic disease-modifying antirheumatic drug; TNF: tumour necrosis factor; IL-6: interleukin 6; CIMT: carotid intima-media thickness.

Supplementary Table S2. Differences between patients on Janus kinase inhibitors and those on other therapies

Variable	Jakinibs n= 8	Other therapies n=138	*p-value*
Baseline demographic and epidemiological characteristics			
Age in years, mean (SD)	52.2 (12.8)	55.9 (12.05)	0.442
Sex (women), n (%)	7 (87.5)	93 (77.5)	0.457
Smoking status			0.447
Never smoker, n (%)	6 (75)	69 (57.5)	-
Ex-smoker, n (%)	0 (0)	20 (16.6)	-
Active smoker, n (%)	2 (25)	26 (21.6)	-
Body mass index (kg/m^2), mean (SD)	25.1 (3.9)	26.6 (4.7)	0.154
Comorbidities			
Hypertension, n (%)	2 (25)	40 (33.3)	0.776
Diabetes mellitus, n (%)	0 (0)	3 (2.5)	0.625
Heart disease, n (%)	1 (12.5)	2 (1.7)	0.081
Dyslipidaemia, n (%)	3 (37.5)	41 (34.1)	0.707
Lab results			
Uric acid (mg/dl), mean (SD)	3.8 (1.1)	4.4 (1.3)	0.065
Total cholesterol (mg/dl), mean (SD)	180.6 (58.6)	195.7 (37.4)	0.402
LDL cholesterol (mg/dl), mean (SD)	117.7 (36.5)	117.1 (29.5)	0.920
HDL cholesterol (mg/dl), mean (SD)	59.7 (16.7)	59.4 (18.8)	0.971
Triglycerides (mg/dl), mean (SD)	91.5 (27.8)	102.1 (47.7)	0.288
Apolipoprotein A1 (mg/dl), mean (SD)	152 (29.5)	150.2 (33.1)	0.886
Apolipoprotein B (mg/dl), mean (SD)	79.5 (35.7)	83.7 (20.03)	0.595
ApoB/ApoA1, mean (SD)	0.6 (0.3)	0.57 (0.2)	0.716
Homocysteine (mg/L), mean (SD)	1.8 (0.4)	3.3 (4.1)	0.060
ESR (mm/h) at visit, mean (SD)	19.6 (14.8)	16.8 (14.8)	0.594
2-year mean ESR, mean (SD)	24.1 (20.1)	17.4 (12.4)	0.367
CRP (mg/dl) at visit, mean (SD)	3.8 (3.9)	8.9 (14.5)	**0.008**
2-year mean CRP, mean (SD)	11.1 (14.9)	9.8 (12)	0.796
Characteristics of the disease			
Disease duration of RA (years), mean (SD)	8.4(8.05)	8.6 (8.3)	**0.004**
Rheumatoid factor positive, n (%)	8 (100)	105 (87.5)	0.891
Anti-CPP positive, n (%)	8 (100)	103 (85.8)	0.220
Anti-CPC level, mean (SD)	256 (152)	317 (439)	0.406
RF level, mean (DE)	115.9 (126.7)	116.4 (193.2)	0.969
Cumulative DAS28, mean (SD)	3.1 (0.9)	2.9 (1.2)	0.844
Remission-low activity, n (%)	6 (75)	62 (51.6)	0.407
Cumulative CDAI, mean (SD)	9.8 (6.02)	10.3 (6.8)	0.608
Cumulative SDAI, mean (SD)	10.7 (6.4)	11.2 (7.3)	0.608
HAQ at visit, mean (SD)	0.68 (0.6)	0.73 (0.7)	0.851
Carotid ultrasound			
CIMT, mean (SD)	0.52 (0.02)	0.64 (0.18)	**<0.001**
Atheromatous plaque, n (%)	1 (12.5)	48 (34.8)	0.190
Bilateral distribution of plaques, n (%)	0 (0)	16 (11.6)	0.299

Abbreviations: jakinibs: Janus kinase inhibitors; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ApoB: apolipoprotein B; ApA1: apolipoprotein A1; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; anti-CCP: anti-cyclic citrullinated peptide, DAS28: 28-joint Disease Activity Score; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; HAQ Health Assessment Questionnaire; bDMARD: biological disease-modifying antirheumatic drug; tsDMARD: targeted synthetic disease-modifying antirheumatic drug; TNF: tumour necrosis factor; IL-6: interleukin 6; CIMT: carotid intima-media thickness.